debt_leverage_profile
0.13x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; debt-light clinical-stage biotech funded primarily by equity; 20bp rate move negligible on minimal debt service
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Single-source tRNA synthetase biologics manufacturing (CMO concentration); U.S.-China API raw material sourcing risk
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; pre-commercial stage with no significant foreign currency exposure in top markets
Inferred
Agent_Inference
geographic_footprint
Primarily U.S.-based operations; negligible sovereign currency devaluation risk given near-zero ex-U.S. commercial revenue
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High; single or dual CMO dependency for proprietary aminoacyl-tRNA synthetase biologics likely exceeds 30% of operational input cost
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biotech; cloud disruption would impair data/trial management but not core drug development IP; 60-90 day recovery feasible
Inferred
Agent_Inference
business_model_type_secondary
No secondary commercial business model; entirely R&D-stage with potential future royalty or partnership licensing revenue
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk to cloud vendors; primary data locked in proprietary biological IP and clinical datasets, not SaaS APIs
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is drug licensing/sales, not investment contracts; equity is standard registered security
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; clinical trial patient data subject to GDPR (EU trials) and CCPA; compliance infrastructure typical for IND-stage biotech
Inferred
Agent_Inference
antitrust_exposure_flag
Low; niche rare disease/inflammatory indication with no dominant market share; orphan drug focus limits antitrust scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% transactional/grant/collaboration milestone-based; no recurring subscription revenue; pre-commercial stage as of 2024
Inferred
Agent_Inference
monetization_vector
Milestone and collaboration payments from partners (e.g., Kyowa Kirin deal); future drug sales royalties upon approval
Inferred
Agent_Inference
pricing_architecture
Orphan/rare disease pricing model; expected WAC $100K-$500K+/year per patient, protected by clinical differentiation and orphan exclusivity
Inferred
Agent_Inference
pricing_power_rating
High potential pricing power given rare disease focus, limited competition, and orphan drug designation for ATYR1923/efzofitimod
Inferred
Agent_Inference
target_gross_margin_bracket
Target 70-85% gross margin post-commercialization; typical biologics rare disease profile assuming CMO manufacturing scale
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; proprietary biologic with patent protection and orphan exclusivity; not applicable in traditional SaaS sense
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth expected post-approval; commercialization requires modest specialty sales force given rare disease narrow patient population
Inferred
Agent_Inference
marginal_cost_of_growth
Low marginal cost of additional patient revenue post-approval; CMO manufacturing scales without proportional headcount increase
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; direct development and potential specialty pharma commercial model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC remains high per physician/patient but amortized over chronic treatment duration; rare disease HCP targeting stays efficient
Inferred
Agent_Inference
network_effect_present
No network effects; biologics drug value independent of user base size; clinical evidence accumulation provides weak indirect effect
Inferred
Agent_Inference
asset_efficiency_ratio
-79.7% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
High resistance; rare/serious inflammatory disease treatment demand inelastic; payer reimbursement (insurance/Medicare) buffers patient price sensitivity
Inferred
Agent_Inference
customer_segment_primary
Specialty physicians (pulmonologists, rheumatologists) treating interstitial lung disease and inflammatory myopathy patients
Inferred
Agent_Inference
customer_segment_secondary
Hospital systems, rare disease patient advocacy networks, and institutional payers/insurers in rare inflammatory disease coverage
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
40.5% CapEx / Revenue (High-CapEx Infrastructure)
High
SEC-XBRL
sec_cik
0001339970
High
SEC-EDGAR
ticker
ATYR
High
SEC-EDGAR